Inhibition of Cyclooxygenase-2 Impairs the Expression of Essential Plasma Cell Transcription Factors and Human B-lymphocyte Differentiation

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2010 Jan 6

PMID 20050331

Citations 13

Authors

Matthew P Bernard

Richard P Phipps

Affiliations

Soon will be listed here.

Abstract

Cyclooxygenase (Cox) inhibitors are among the most widely used and commonly prescribed medications. Relatively little is understood about their influence on human immune responses. Herein, we discovered a novel and important mechanism whereby non-steroidal anti-inflammatory drugs (NSAIDs) blunt human B-cell antibody production. We demonstrate that the Cox-2 selective small molecule inhibitors SC-58125 and NS-398 attenuate the production of human antibody isotypes including immunoglobulin M (IgM), IgG1, IgG2, IgG3 and IgG4. In addition, inhibition of Cox-2 significantly reduced the generation of CD38+ IgM+ and CD38+ IgG+ antibody-secreting cells. Interestingly, we discovered that inhibition of Cox-2 activity in normal human B cells severely reduced the messenger RNA and protein levels of the essential plasma cell transcription factor, Blimp-1. These observations were mirrored in Cox-2-deficient mice, which had reduced CD138+ plasma cells and a near loss of Blimp-1 expression. These new findings demonstrate a critical role for Cox-2 in the terminal differentiation of human B lymphocytes to antibody-secreting plasma cells. The use of NSAIDs may adversely influence the efficacy of vaccines, especially in the immunocompromised, elderly and when vaccines are weakly immunogenic.

Citing Articles

D1-like dopamine receptors promote B-cell differentiation in systemic lupus erythematosus.

Xiang Z, Wu F, He Z, Tan F, Hu H, Zou C Cell Commun Signal. 2024; 22(1):502.

PMID: 39420360 PMC: 11484144. DOI: 10.1186/s12964-024-01885-3.

Influence of Inhibition of COX-2-Dependent Lipid Metabolism on Regulation of UVB-Induced Keratinocytes Apoptosis by Cannabinoids.

Wojcik P, Biernacki M, Domian N, Zarkovic N, Skrzydlewska E Biomolecules. 2022; 12(6).

PMID: 35740969 PMC: 9220871. DOI: 10.3390/biom12060842.

Cyclooxygenase 2 (Cox 2) Expression in Newly Diagnosed Plasma Cell Myeloma: A Clinicopathological and Immunohistochemical Study on 73 Cases from a Single Tertiary Care Center.

Pattnaik S, Padhi S, Panigrahi A, Sharma G Indian J Hematol Blood Transfus. 2022; 38(2):235-245.

PMID: 35496959 PMC: 9001773. DOI: 10.1007/s12288-021-01448-3.

Inhibition of COX-2 ameliorates murine liver schistosomiasis japonica through splenic cellular immunoregulation.

Qi Z, Lan C, Xiaofang J, Juanjuan T, Cheng F, Ting H Parasit Vectors. 2022; 15(1):144.

PMID: 35461268 PMC: 9034617. DOI: 10.1186/s13071-022-05201-1.

Oxidative Stress and Lipid Mediators Modulate Immune Cell Functions in Autoimmune Diseases.

Wojcik P, Gegotek A, Zarkovic N, Skrzydlewska E Int J Mol Sci. 2021; 22(2).

PMID: 33450863 PMC: 7828321. DOI: 10.3390/ijms22020723.

References

Nivsarkar M, Banerjee A, Padh H . Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008; 60(5):692-8. View

Iwakoshi N, Lee A, Vallabhajosyula P, Otipoby K, Rajewsky K, Glimcher L . Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003; 4(4):321-9. DOI: 10.1038/ni907. View

Lindroth K, Fernandez C . The role of Blimp-1 in the GC reaction: differential expression of Blimp-1 upon immunization with TD and TI antigens. Immunol Lett. 2007; 113(2):70-5. DOI: 10.1016/j.imlet.2007.07.018. View

Turull A, Queralt J . Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats. Immunopharmacology. 2000; 46(1):71-7. DOI: 10.1016/s0162-3109(99)00159-9. View

Jana N . NSAIDs and apoptosis. Cell Mol Life Sci. 2008; 65(9):1295-301. PMC: 11131660. DOI: 10.1007/s00018-008-7511-x. View

Hanten J, Vasilakos J, Riter C, Neys L, Lipson K, Alkan S . Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008; 9:39. PMC: 2503978. DOI: 10.1186/1471-2172-9-39. View

Brewer J, Hendershot L . Building an antibody factory: a job for the unfolded protein response. Nat Immunol. 2004; 6(1):23-9. DOI: 10.1038/ni1149. View

Shapiro-Shelef M, Lin K, McHeyzer-Williams L, Liao J, McHeyzer-Williams M, Calame K . Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003; 19(4):607-20. DOI: 10.1016/s1074-7613(03)00267-x. View

Avery D, Ellyard J, Mackay F, Corcoran L, Hodgkin P, Tangye S . Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol. 2005; 174(7):4034-42. DOI: 10.4049/jimmunol.174.7.4034. View

10.

Tirosh B, Iwakoshi N, Glimcher L, Ploegh H . XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells. J Exp Med. 2005; 202(4):505-16. PMC: 2212843. DOI: 10.1084/jem.20050575. View

11.

Ryan E, Malboeuf C, Bernard M, Rose R, Phipps R . Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J Immunol. 2006; 177(11):7811-9. DOI: 10.4049/jimmunol.177.11.7811. View

12.

Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, McKenzie B . Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity. 2007; 26(5):555-66. DOI: 10.1016/j.immuni.2007.04.007. View

13.

Chen Y, Zhang J, Moore S, Ballas Z, Portanova J, Krieg A . CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol. 2001; 13(8):1013-20. DOI: 10.1093/intimm/13.8.1013. View

14.

Ryan E, Pollock S, Pollack S, Murant T, Bernstein S, Felgar R . Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol. 2005; 174(5):2619-26. DOI: 10.4049/jimmunol.174.5.2619. View

15.

Hasbold J, Corcoran L, Tarlinton D, Tangye S, Hodgkin P . Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol. 2003; 5(1):55-63. DOI: 10.1038/ni1016. View

16.

Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V . Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002; 100(4):1113-22. View

17.

Bernard M, Bancos S, Sime P, Phipps R . Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des. 2008; 14(21):2051-60. PMC: 2745246. DOI: 10.2174/138161208785294654. View

18.

Bernard M, Phipps R . CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production. Clin Immunol. 2007; 125(2):138-48. PMC: 2197160. DOI: 10.1016/j.clim.2007.07.006. View

19.

Kallies A, Nutt S . Terminal differentiation of lymphocytes depends on Blimp-1. Curr Opin Immunol. 2007; 19(2):156-62. DOI: 10.1016/j.coi.2007.01.003. View

20.

Shapiro-Shelef M, Lin K, Savitsky D, Liao J, Calame K . Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med. 2005; 202(11):1471-6. PMC: 2213334. DOI: 10.1084/jem.20051611. View